全文获取类型
收费全文 | 1182篇 |
免费 | 155篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 8篇 |
妇产科学 | 8篇 |
基础医学 | 25篇 |
口腔科学 | 19篇 |
临床医学 | 322篇 |
内科学 | 477篇 |
皮肤病学 | 8篇 |
神经病学 | 82篇 |
特种医学 | 4篇 |
外科学 | 93篇 |
综合类 | 38篇 |
现状与发展 | 1篇 |
预防医学 | 32篇 |
眼科学 | 5篇 |
药学 | 212篇 |
中国医学 | 1篇 |
肿瘤学 | 19篇 |
出版年
2023年 | 27篇 |
2022年 | 58篇 |
2021年 | 73篇 |
2020年 | 110篇 |
2019年 | 108篇 |
2018年 | 112篇 |
2017年 | 84篇 |
2016年 | 75篇 |
2015年 | 73篇 |
2014年 | 89篇 |
2013年 | 124篇 |
2012年 | 35篇 |
2011年 | 37篇 |
2010年 | 24篇 |
2009年 | 30篇 |
2008年 | 24篇 |
2007年 | 29篇 |
2006年 | 25篇 |
2005年 | 24篇 |
2004年 | 17篇 |
2003年 | 28篇 |
2002年 | 13篇 |
2001年 | 12篇 |
2000年 | 11篇 |
1999年 | 5篇 |
1998年 | 8篇 |
1997年 | 7篇 |
1996年 | 7篇 |
1995年 | 9篇 |
1994年 | 5篇 |
1993年 | 9篇 |
1992年 | 3篇 |
1991年 | 8篇 |
1990年 | 7篇 |
1989年 | 4篇 |
1988年 | 4篇 |
1987年 | 2篇 |
1986年 | 1篇 |
1985年 | 7篇 |
1984年 | 8篇 |
1983年 | 6篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1978年 | 3篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1974年 | 1篇 |
排序方式: 共有1358条查询结果,搜索用时 15 毫秒
1.
Rohi Shah Nomaan Sheikh Jitendra Mangwani Nicolette Morgan Hamidreza Khairandish 《Journal of Clinical Orthopaedics and Trauma》2021,12(1):138
Demographic projections for hip fragility fractures indicate a rising annual incidence by virtue of a multimorbid, ageing population with more noncommunicable diseases (NCDs). NCDs are characterised by slow progression and long duration ranging from ischaemic cardiovascular disease, cerebrovascular disease, diabetes, chronic obstructive pulmonary disease to various cancers. Management of this disease burden often involves commencing patients on oral anticoagulants to reduce the risk of thromboembolic events. The use of direct oral anticoagulants (DOACs) in clinical practice has increased due to their rapid onset of action, short half-life and predictable anticoagulant effects, without the need for routine monitoring. Safe and timely surgical intervention relies on reversal of anticoagulants. However, the lack of specific evidence-based guidelines for the perioperative management of patients on DOACs with hip fractures has proved challenging; in particular, the accessibility of DOAC-specific assays, justification of the cost-benefit ratio of targeted reversal agents and indications for neuraxial anaesthesia. This has led to potentially avoidable delays in surgical intervention. Following a literature review of the pharmacokinetic and pharmacodynamics of commonly used DOACs in our region including the role of surrogate markers, we propose a systematic, evidence-based guideline to the perioperative management of hip fractures DOACs. We believe this standardised protocol can be easily replicated between hospitals. We recommend that if patients are deemed suitable for a general anaesthesia, with satisfactory renal function, optimal surgical time should be 24 h following the last ingested dose of DOAC. 相似文献
2.
Conan MacDougall Theora Canonica Chris Keh Binh An P. Phan Janice Louie 《Pharmacotherapy》2022,42(4):343-361
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs. 相似文献
3.
K. KARNICKI† R. D. MCBANE II † R. S. MILLER† R. J. Leadley JR ¶ J. MORSER W. G. OWEN†‡ J. H. CHESEBRO§ 《Journal of thrombosis and haemostasis》2004,2(12):2162-2169
BACKGROUND/OBJECTIVE: The efficacy of a direct factor (F)Xa inhibitor, ZK-807834, was compared with indirect inhibition by enoxaparin for inhibition and deaggregation of acute platelet-rich thrombi in a well-characterized porcine carotid injury model. METHODS: A crush injury was performed on a randomly chosen carotid artery and the thrombus allowed to propagate for 30 min. Pigs then received intravenous drug for 35 min: ZK-807834-Dose 1 (40 microg kg(-1) bolus + 1.5 microg kg(-1) min(-1) infusion, n=6); ZK-807834-Dose 2 (20 microg kg(-1) bolus + 0.75 microg kg(-1) min(-1) infusion; n=6); enoxaparin (1 mg kg(-1) bolus; n=6); or saline (n=6). Five minutes after drug initiation, the contralateral artery was injured. Thrombus size was monitored by scintillation detection of autologous 111In-platelets. RESULTS: The prothrombin time ratio was 2.2 +/- 0.1; 1.4 +/- 0.3; 1.2 +/- 0.9 and 1.1 +/- 0.2, respectively. ZK-807834-Dose 1 significantly inhibited carotid platelet deposition (525 +/- 226 x 10(6) cm(-2); P = 0.008), whereas ZK-807834-Dose 2 (2325 +/- 768) and enoxaparin (1236 +/- 383) were not different from saline (2776 +/- 642). Thrombus deaggregation was greatest for animals receiving ZK-807834-Dose 1 (473 +/- 185). Neither ZK-807834-Dose 2 (1588 +/- 480) nor enoxaparin (1618 +/- 686) was different from saline control (2222 +/- 598). CONCLUSIONS: Direct FXa inhibition with ZK-807834, at a prothrombin time ratio of 2.2, effectively inhibits thrombosis and promptly deaggregates thrombi induced by arterial injury. In contrast, indirect FXa inhibition with enoxaparin was ineffective. 相似文献
4.
5.
Anticoagulant Activity of Fucoidan from Brown Algae Fucus evanescens of the Okhotsk Sea 总被引:2,自引:0,他引:2
Kuznetsova TA Besednova NN Mamaev AN Momot AP Shevchenko NM Zvyagintseva TN 《Bulletin of experimental biology and medicine》2003,136(5):471-473
In vitro and in vivo experiments showed that anticoagulant activity of sulfated polysaccharide from Fucus evanescens (brown algae of the Okhotsk Sea) was similar to that of heparin. Anticoagulant properties of fucoidan are determined by thrombin inhibition mediated via plasma antithrombin III. 相似文献
6.
顽固性心绞痛治疗进展 总被引:1,自引:0,他引:1
黄震华 《中国新药与临床杂志》2004,23(10):708-712
顽固性心绞痛是指传统的抗心绞痛药物均无效 ,又不适合做冠状动脉内介入治疗和冠脉搭桥术的心绞痛。新的药物治疗 (新的抗血小板药物、低分子肝素、溶栓药物、抗心肌缺血的代谢疗法 )、神经刺激、增强的体外反搏、激光血管重建术、基因治疗、经皮穿刺心肌静脉动脉化、心脏移植代表了目前顽固性心绞痛治疗上的新的探索 相似文献
7.
8.
9.
10.